16:55 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Frequency's FX-322 well tolerated in Phase I hearing loss study

Frequency Therapeutics Inc. (Woburn, Mass.) reported preliminary data from nine patients with severe to profound sensorineural hearing loss in a Phase I trial showing that intratympanic FX-322 within 24 hours prior to receiving a cochlear...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...